Glenmark Pharmaceuticals Share Price Today (GLENMARK)
TODAY IN ONE LINE
GLENMARK fell 1.4% on average volume, in line with Nifty's -0.8% move, supported by recent strong earnings.
With a market cap of ₹62,419.99 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Glenmark Pharmaceuticals flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 6575.0% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 15.8% and Profit up 51.9%
- ●High Capital EfficiencyROCE of 39.8% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 30.5%
- ●Healthy Operating MarginsOPM is structurally strong at 26.9%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 39.4% outpacing sales growth of 12.8%
Latest Glenmark Pharmaceuticals News
What changed recently?
Recent events, corporate actions, and announcements.
Glenmark Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Glenmark Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Glenmark Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Glenmark Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
Glenmark Pharmaceuticals Limited last traded at ₹2,211.9 with an intraday range of ₹2,166–₹2,229.8 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2211.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2366.73 | +154.83 | +7.00% |
| R3 | 2302.93 | +91.03 | +4.12% |
| R2 | 2266.37 | +54.47 | +2.46% |
| R1 | 2239.13 | +27.23 | +1.23% |
| PIVOT | 2202.57 | -9.33 | -0.42% |
| CURRENT | 2211.90 | — | — |
| S1 | 2175.33 | -36.57 | -1.65% |
| S2 | 2138.77 | -73.13 | -3.31% |
| S3 | 2111.53 | -100.37 | -4.54% |
| S4 | 2047.73 | -164.17 | -7.42% |
GLENMARK is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹2166–₹2229.8
Trading Below opening range, showing Bearishness
Glenmark Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Glenmark Pharmaceuticals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Glenmark Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹62,419.99 Cr. and reported EPS of ₹48.15.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 13,322 | 16,983 ▲ 27.5% |
| Sales Growth YoY %Derived | 12.77% | 27.48% |
| Other Income | 114 | 461 ▲ 305.0% |
| Total Income | 13,435 | 17,443 ▲ 29.8% |
| 4,353 | 4,747 ▲ 9.1% | |
| Gross ProfitDerived | 8,968 | 12,235 ▲ 36.4% |
| Gross Margin %Derived | 67.32% | 72.04% |
| 6,617 | 7,663 ▲ 15.8% | |
| EBITDA (Operating Profit)Derived | 2,351 | 4,572 ▲ 94.5% |
| OPM %Derived | 17.65% | 26.92% |
| 320 | -1,484 ▼ 563.3% | |
| Profit Before Tax (PBT) | 1,399 | 1,985 ▲ 41.8% |
| 352 | 623 ▲ 76.9% | |
| Effective Tax %Derived | 25.16% | 31.38% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 1,047 | 1,362 ▲ 30.1% |
| Less: Non-controlling Interests | 0 | 1,362 ▲ 3026235.6% |
| Net Profit (Owner's PAT)Derived | 1,047 | 0 ▼ 100.0% |
| Net Profit Margin %Derived | 7.86% | 0.00% |
| PAT Growth YoY %Derived | 169.73% | -99.99% |
| Earnings Per Share (EPS ₹) | 37.11 | — ▼ 100.0% |
| Diluted Shares Outstanding (Cr) | 28 | 28 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 64 | 414 ▲ 545.4% |
| Total Expenses (incl. D&A & Interest) | 12,036 | 15,458 ▲ 28.4% |
| Material Cost % of RevenueDerived | 22.53% | 17.44% |
| Employee Cost % of RevenueDerived | 22.69% | 21.07% |
| Other Cost % of RevenueDerived | 26.99% | 24.05% |
| Interest Coverage (x)Derived | 9.01x | 19.16x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 9,103 | 9,865 ▲ 8.4% | 10,641 ▲ 7.9% | 10,944 ▲ 2.8% | 12,305 ▲ 12.4% | 12,990 ▲ 5.6% | 11,813 ▼ 9.1% | 13,322 ▲ 12.8% | 16,983 ▲ 27.5% | |
| Sales Growth YoY %Derived | — | 8.38% | 7.86% | 2.85% | 12.44% | 5.57% | -9.06% | 12.77% | 27.48% | |
| Other Income | 91 | 208 ▲ 127.7% | 160 ▼ 23.3% | 50 ▼ 68.5% | 167 ▲ 231.9% | 317 ▲ 90.1% | 840 ▲ 165.2% | 114 ▼ 86.5% | 461 ▲ 305.0% | |
| Total Income | 9,194 | 10,074 ▲ 9.6% | 10,801 ▲ 7.2% | 10,994 ▲ 1.8% | 12,472 ▲ 13.4% | 13,307 ▲ 6.7% | 12,653 ▼ 4.9% | 13,435 ▲ 6.2% | 17,443 ▲ 29.8% | |
3,039 | 3,362 ▲ 10.7% | 3,699 ▲ 10.0% | 3,699 ▲ 0.0% | 4,385 ▲ 18.6% | 4,537 ▲ 3.5% | 4,413 ▼ 2.7% | 4,353 ▼ 1.4% | 4,747 ▲ 9.1% | ||
| Gross ProfitDerived | 6,065 | 6,503 ▲ 7.2% | 6,942 ▲ 6.8% | 7,245 ▲ 4.4% | 7,920 ▲ 9.3% | 8,453 ▲ 6.7% | 7,400 ▼ 12.5% | 8,968 ▲ 21.2% | 12,235 ▲ 36.4% | |
| Gross Margin %Derived | 66.62% | 65.92% | 65.24% | 66.20% | 64.36% | 65.07% | 62.64% | 67.32% | 72.04% | |
4,449 | 4,917 ▲ 10.5% | 5,244 ▲ 6.6% | 5,161 ▼ 1.6% | 5,599 ▲ 8.5% | 6,175 ▲ 10.3% | 6,204 ▲ 0.5% | 6,617 ▲ 6.7% | 7,663 ▲ 15.8% | ||
| EBITDA (Operating Profit)Derived | 1,615 | 1,586 ▼ 1.8% | 1,698 ▲ 7.1% | 2,084 ▲ 22.7% | 2,320 ▲ 11.3% | 2,278 ▼ 1.8% | 1,195 ▼ 47.5% | 2,351 ▲ 96.7% | 4,572 ▲ 94.5% | |
| OPM %Derived | 17.75% | 16.07% | 15.96% | 19.05% | 18.86% | 17.54% | 10.12% | 17.65% | 26.92% | |
587 | 828 ▲ 40.9% | 827 ▼ 0.0% | 841 ▲ 1.7% | 524 ▼ 37.7% | 195 ▼ 62.8% | 197 ▲ 1.0% | 320 ▲ 62.6% | -1,484 ▼ 563.3% | ||
| Profit Before Tax (PBT) | 1,119 | 1,301 ▲ 16.2% | 1,096 ▼ 15.7% | 1,382 ▲ 26.1% | 1,441 ▲ 4.3% | 868 ▼ 39.7% | 36 ▼ 95.8% | 1,399 ▲ 3734.0% | 1,985 ▲ 41.8% | |
315 | 376 ▲ 19.1% | 320 ▼ 14.8% | 412 ▲ 28.8% | 448 ▲ 8.5% | 491 ▲ 9.7% | 1,867 ▲ 280.3% | 352 ▼ 81.1% | 623 ▲ 76.9% | ||
| Effective Tax %Derived | 28.18% | 28.88% | 29.20% | 29.83% | 31.06% | 56.54% | 5,116.72% | 25.16% | 31.38% | |
| Profit/Loss from Discontinued Ops | — | — | — | — | — | — | 397 | — ▼ 100.0% | — | |
| Total Profit for Period | 804 | 925 ▲ 15.1% | 776 ▼ 16.1% | 970 ▲ 25.0% | 994 ▲ 2.4% | 377 ▼ 62.0% | -1,434 ▼ 479.8% | 1,047 ▲ 173.0% | 1,362 ▲ 30.1% | |
| Less: Non-controlling Interests | — | — | — | — | 52 | — ▼ 100.0% | 68 | 0 ▼ 99.9% | 1,362 ▲ 3026235.6% | |
| Net Profit (Owner's PAT)Derived | 804 | 925 ▲ 15.1% | 776 ▼ 16.1% | 970 ▲ 25.0% | 942 ▼ 2.9% | 377 ▼ 59.9% | -1,502 ▼ 497.9% | 1,047 ▲ 169.7% | 0 ▼ 100.0% | |
| Net Profit Margin %Derived | 8.83% | 9.38% | 7.29% | 8.86% | 7.65% | 2.91% | -12.71% | 7.86% | 0.00% | |
| PAT Growth YoY %Derived | — | 15.07% | -16.11% | 25.02% | -2.93% | -59.92% | -497.90% | 169.73% | -99.99% | |
| Earnings Per Share (EPS ₹) | 28.49 | 32.78 ▲ 15.1% | 27.50 ▼ 16.1% | 34.38 ▲ 25.0% | 33.37 ▼ 2.9% | 13.38 ▼ 59.9% | -53.22 ▼ 497.8% | 37.11 ▲ 169.7% | — ▼ 100.0% | |
| Diluted Shares Outstanding (Cr) | 28 | 28 ▲ 0.0% | 28 ▲ 0.0% | 28 ▲ 0.0% | 28 ▲ 0.0% | 28 ▲ 0.0% | 28 ▲ 0.0% | 28 ▲ 0.0% | 28 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -74 | -415 ▼ 461.3% | -246 ▲ 40.8% | 87 ▲ 135.3% | 77 ▼ 11.5% | 154 ▲ 100.4% | -66 ▼ 142.6% | 64 ▲ 197.9% | 414 ▲ 545.4% | |
| Total Expenses (incl. D&A & Interest) | 8,075 | 8,773 ▲ 8.6% | 9,704 ▲ 10.6% | 9,612 ▼ 1.0% | 11,030 ▲ 14.8% | 12,438 ▲ 12.8% | 12,617 ▲ 1.4% | 12,036 ▼ 4.6% | 15,458 ▲ 28.4% | |
| Material Cost % of RevenueDerived | 23.62% | 24.78% | 23.88% | 28.67% | 26.65% | 27.67% | 26.73% | 22.53% | 17.44% | |
| Employee Cost % of RevenueDerived | 20.56% | 20.84% | 21.19% | 21.42% | 19.89% | 21.41% | 24.28% | 22.69% | 21.07% | |
| Other Cost % of RevenueDerived | 28.31% | 29.00% | 28.09% | 25.74% | 25.62% | 26.13% | 28.24% | 26.99% | 24.05% | |
| Interest Coverage (x)Derived | 4.60x | 3.77x | 3.39x | 4.65x | 6.15x | 4.77x | 1.19x | 9.01x | 19.16x |
Glenmark Pharmaceuticals segment analysis : revenue and profit mix.
Disclosed business segments at Glenmark Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Glenmark Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Glenmark Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting Glenmark Pharmaceuticals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Glenmark Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 23.93% demonstrates strong pricing power and operational efficiency.
ROCE 39.80% and ROE 30.50% indicate highly efficient capital deployment and returns.
Low debt-to-equity 0.0006 maintains minimal financial leverage and risk profile.
Promoter holding 46.65% aligns management incentives with long-term shareholder value.
TTM revenue growth 14.30% outpaces many mid-cap pharma peers in competitive market.
Key Risks.
Latest quarterly profit declined 23.50% YoY despite 15.80% revenue growth momentum.
Net profit margin 8.15% lags peer averages, compressing earnings conversion efficiency.
P/E ratio 45.46x significantly exceeds peer median, signals premium valuation risk.
Price-to-book 6.09x elevated relative to historical tangible book value trends.
Quarterly sales growth 0.62% YoY indicates stagnant near-term revenue momentum.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 26% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.11%.
Glenmark Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Glenmark Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Glenmark Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Glenmark Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Glenmark Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Glenmark Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Glenmark Pharmaceuticals Limited stood at 44.5% of traded volume, against a 20-day average of 46.7%.
Glenmark Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Glenmark Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Glenmark Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 165 documents below.
Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 06, 2026, titled "Glenmark Pharmaceuticals Inc., USA…
Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country…
Analysts/Institutional Investor Meet/Con. Call Updates
Glenmark Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Trading Window
Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 17, 2026, titled "Glenmark Pharmaceuticals Inc., USA…
Investor decks & rating reports.
Glenmark Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Glenmark Pharmaceuticals has declared, sequenced by announce and record date.
Glenmark Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Glenmark Pharmaceuticals Limited: business, sector, key facts.
What Glenmark Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Glenmark Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GLENMARK, BSE: 532296.
Glenmark Pharmaceuticals is a global pharmaceutical company engaged in the development, manufacturing, and sale of a diverse range of pharmaceutical products. Their portfolio encompasses generic medications, specialty pharmaceuticals, and over-the-counter (OTC) drugs, distributed across major global markets including India, North America, Latin America, and Europe. The company’s manufacturing capabilities span various dosage forms, including complex injectables and biologics, oral solids and liquids, topical products, drops, and respiratory inhalers (MDI/DPI/nasal sprays).
Glenmark focuses on several key therapeutic areas, offering branded and generic formulations for dermatological conditions, respiratory illnesses, oncology treatments, cardiovascular diseases, diabetes, gynecological issues, gastroenterological problems, and anti-infective therapies. This broad therapeutic reach allows them to cater to a wide patient base and diverse healthcare needs.
A significant aspect of Glenmark's business strategy is its robust research and development (R&D) pipeline. The company is actively involved in the development of innovative new therapies, focusing primarily on oncology and immunology. Notable examples include ISB 2001, a trispecific antibody targeting multiple myeloma; ISB 1442, a bispecific antibody also targeting multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor for solid tumors. Furthermore, their pipeline features investigational treatments for autoimmune diseases, such as ISB 880 (an IL-1RAP antagonist) and ISB 830 (a telazorlimab OX40 antagonist), which are currently undergoing clinical trials.
Beyond its R&D efforts, Glenmark also markets established products, including Ryaltris, a nasal spray indicated for seasonal allergic rhinitis. This demonstrates a balanced approach, combining innovation with the commercialization of existing, effective therapies. The company's long history, established in 1977 and headquartered in Mumbai, India, provides a strong foundation for its continued growth and global presence within the pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Glenmark Pharmaceuticals Limited (GLENMARK).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Glenmark Pharmaceuticals Limited (GLENMARK)?
The current share price of Glenmark Pharmaceuticals Limited (GLENMARK) is ₹2,211.9. Today, the stock has declined by ₹30.20 (1.35%), trading in a range of ₹2,166 to ₹2,229.8. The stock opened at ₹2,229.8 with a trading volume of 7,74,232 shares.
02Is Glenmark Pharmaceuticals Limited stock a good investment for long-term?
Glenmark Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹62,419.99 crores, P/E ratio of 0.00, ROE of 30.50%, and ROCE of 39.80%. The dividend yield stands at 0.22%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Glenmark Pharmaceuticals Limited stock?
The 52-week high price of Glenmark Pharmaceuticals Limited (GLENMARK) is ₹2,474, while the 52-week low is ₹1,792.6. Currently trading at ₹2,211.9, the stock is 61.5% away from its 52-week low and 10.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Glenmark Pharmaceuticals Limited stock at the current price?
Whether to buy Glenmark Pharmaceuticals Limited stock at ₹2,211.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 6.01. Today's performance shows a loss of 1.35%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Glenmark Pharmaceuticals Limited and when is the next dividend?
Glenmark Pharmaceuticals Limited offers a dividend yield of 0.22%, which means for every ₹100 invested at the current price of ₹2,211.9, you can expect to receive approximately ₹0.22 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 6.01, ROE: 30.50%, ROCE: 39.80%, Dividend Yield: 0.22%, EPS: ₹48.15, Book Value: ₹372.48, and Debt-to-Equity: 0.06. The company's market cap stands at ₹62,419.99 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Glenmark Pharmaceuticals Limited stock performing today in the market?
Glenmark Pharmaceuticals Limited stock opened at ₹2,229.8 and is currently trading at ₹2,211.9, showing a decline of ₹30.20 (1.35%). The intraday high is ₹2,229.8 and low is ₹2,166. The trading volume stands at 7,74,232 shares, indicating moderate market participation today.
08What is the P/E ratio of Glenmark Pharmaceuticals Limited and what does it indicate?
Glenmark Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹48.15, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Glenmark Pharmaceuticals Limited (GLENMARK) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.